Chemoproteomic Evaluation of Target Engagement by the Cyclin-Dependent Kinase 4 and 6 Inhibitor Palbociclib Correlates with Cancer Cell Response-Reference-Cited by-同舟云学术

Chemoproteomic Evaluation of Target Engagement by the Cyclin-Dependent Kinase 4 and 6 Inhibitor Palbociclib Correlates with Cancer Cell Response

Published:2016-09-13 Issue:38 Volume:55 Page:5434-5441
ISSN:0006-2960
Container-title:Biochemistry
language:en
Short-container-title:Biochemistry

Author:

Nomanbhoy Tyzoon K.¹,Sharma Geeta²,Brown Heidi¹,Wu Jiangyue¹,Aban Arwin¹,Vogeti Subha²,Alemayehu Senait¹,Sykes Maria¹,Rosenblum Jonathan S.¹,Kozarich John W.¹

Affiliation:

1. ActivX Biosciences, 11025 N. Torrey Pines Road, Suite 120, La Jolla, California 92037, United States

2. Agilux Laboratories, Three Biotech, One Innovation Drive, Worcester, Massachusetts 01605, United States

Funder

Kyorin pharmaceuticals

Publisher

American Chemical Society (ACS)

Subject

Biochemistry

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.biochem.6b00629

Reference23 articles.

1. Targeting cancer with small molecule kinase inhibitors

2. FDA-approved small-molecule kinase inhibitors

3. Kinase Drug Discovery – What’s Next in the Field?

4. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. High-throughput screening identifies cell cycle-associated signaling cascades that regulate a multienzyme glucosome assembly in human cells;PLOS ONE;2023-08-04

2. Targeting RAF Isoforms and Tumor Microenvironments in RAS or BRAF Mutant Colorectal Cancers with SJ-C1044 for Anti-Tumor Activity;Current Issues in Molecular Biology;2023-07-13

3. PIP5K1C phosphoinositide kinase deficiency distinguishes PIKFYVE-dependent cancer cells from non-malignant cells;Autophagy;2023-03-22

4. Preclinical evaluation of CDK4 phosphorylation predicts high sensitivity of pleural mesotheliomas to CDK4 /6 inhibition;Molecular Oncology;2022-12-19

5. Escape from G1 arrest during acute MEK inhibition drives the acquisition of drug resistance;NAR Cancer;2022-09-28